Da-Peng Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Da-Peng Lu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Caigang Liu
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication - Feng Jin
Department of Breast Surgery The First Hospital of China Medical University Shenyang Liaoning China
1 shared publication - Lutian Yao
Department of Orthopedic, The First Affiliated Hospital of China Medical University
1 shared publication - Wei Ma
Department of Breast Surgery, First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, PR China
1 shared publication - Xiang-Yu Zhou
Department of General surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang 110032, Liaoning, China
1 shared publication - Yun-Fei Wu
Department of Breast Surgery, First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, PR China.
1 shared publication
Latest Publications
- Open Access
- 18 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 198
Serum soluble ST2 is associated with ER-positive breast cancer
Background: ST2, a member of the interleukin (IL)-1receptor family, regulates Th1/Th2 immune responses in autoimmune and inflammatory conditions. However, the role of ST2 signaling in tumor growth and metastasis of breast cancers has not been investigated. This study investigated the possible role of soluble ST2 (sST2) in breast cancer. Methods: The serum levels of IL-33, sST2, and vascular endothelial growth factor (VEGF) in 150 breast cancer patients and 90 healthy women were measured by enzyme-linked immunosorbent assay. Estrogen receptor(ER), progesterone receptor, human epithelial receptor (HER)-2, and cell cycle regulated protein Ki-67 were measured. Clinical stage, tumor size, lymph node metastasis, and histological type were also recorded. Results: The serum levels of sST2, IL-33, and VEGF were significantly higher in breast cancer patients than in the control group (P < 0.05, each). Serum sST2 levels in ER-positive breast cancer patients were significantly associated with age, histological type, clinical stage, tumor size, and Ki-67 status (P < 0.05, each). Moreover, the serum levels of IL-33 and sST2 in breast cancers significantly correlated with VEGF levels (IL-33: r = 0.375, P < 0.0001; sST2: r = 0.164, P = 0.045). Serum levels of sST2, IL-33, and VEGF decreased after modified radical mastectomy in ER-positive breast cancers. Serum levels of IL-33, sST2, and VEGF and clinicopathological factors were not significantly correlated with disease-free survival and overall survival of ER-positive breast cancer women during follow-up. Conclusion: Serum sST2 levels in ER-positive breast cancer patients are significantly associated with factors that indicate poor prognosis.
- 18 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 198
Open AccessSerum soluble ST2 is associated with ER-positive breast cancer
Background: ST2, a member of the interleukin (IL)-1receptor family, regulates Th1/Th2 immune responses in autoimmune and inflammatory conditions. However, the role of ST2 signaling in tumor growth and metastasis of breast cancers has not been investigated. This study investigated the possible role of soluble ST2 (sST2) in breast cancer. Methods: The serum levels of IL-33, sST2, and vascular endothelial growth factor (VEGF) in 150 breast cancer patients and 90 healthy women were measured by enzyme-linked immunosorbent assay. Estrogen receptor(ER), progesterone receptor, human epithelial receptor (HER)-2, and cell cycle regulated protein Ki-67 were measured. Clinical stage, tumor size, lymph node metastasis, and histological type were also recorded. Results: The serum levels of sST2, IL-33, and VEGF were significantly higher in breast cancer patients than in the control group (P < 0.05, each). Serum sST2 levels in ER-positive breast cancer patients were significantly associated with age, histological type, clinical stage, tumor size, and Ki-67 status (P < 0.05, each). Moreover, the serum levels of IL-33 and sST2 in breast cancers significantly correlated with VEGF levels (IL-33: r = 0.375, P < 0.0001; sST2: r = 0.164, P = 0.045). Serum levels of sST2, IL-33, and VEGF decreased after modified radical mastectomy in ER-positive breast cancers. Serum levels of IL-33, sST2, and VEGF and clinicopathological factors were not significantly correlated with disease-free survival and overall survival of ER-positive breast cancer women during follow-up. Conclusion: Serum sST2 levels in ER-positive breast cancer patients are significantly associated with factors that indicate poor prognosis.